Details of the Drug Reposition

General Information of This Drug (ID: DMDGPKS)

Drug Name
RG7625   DMDGPKS
Synonyms
Petesicatib; UNII-A26QO95U37; A26QO95U37; RG-7625; RO-5459072; Petesicatib [INN]; SCHEMBL700776; GTPL9855; KXAAIORSMACJSI-AEFFLSMTSA-N; RO5459072; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; 1252637-35-6; (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; (2s,4r)-4-[4-(1-me
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Autoimmune disease DISORMTM 4A40-4A45 Phase 2 [1]
Sjogren syndrome DISUBX7H 4A43.20 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coeliac disease DISIY60C DA95 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)